Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Martin Wisher
Advertisement
Martin Wisher, PHD, is senior director, global head of regulatory affairs for BioReliance at MilliporeSigma.
Articles by Martin Wisher
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5